Using newer vaccine platforms which have been effective against malaria in rodent models, we tested five immunization regimens against Plasmodium knowlesi in rhesus monkeys. All vaccines included the same four P. knowlesi antigens: the pre-erythrocytic antigens CSP, SSP2, and erythrocytic antigens AMA1, MSP1. We used four vaccine platforms for prime or boost vaccinations: plasmids (DNA), alphavirus replicons (VRP), attenuated adenovirus serotype 5 (Ad), or attenuated poxvirus (Pox). These four platforms combined to produce five different prime/boost vaccine regimens: Pox alone, VRP/Pox, VRP/Ad, Ad/Pox, and DNA/Pox. Five rhesus monkeys were immunized with each regimen, and five Control monkeys received a mock vaccination. The time to complete vaccinations was 420 days. All monkeys were challenged twice with 100 P. knowlesi sporozoites given IV. The first challenge was given 12 days after the last vaccination, and the monkeys receiving the DNA/Pox vaccine were the best protected, with 3/5 monkeys sterilely protected and 1/5 monkeys that self-cured its parasitemia. There was no protection in monkeys that received Pox malaria vaccine alone without previous priming. The second sporozoite challenge was given 4 months after the first. All 4 monkeys that were protected in the first challenge developed malaria in the second challenge. DNA, VRP and Ad5 vaccines all primed monkeys for strong immune responses after the Pox boost. We discuss the high level but short duration of protection in this experiment and the possible benefits of the long interval between prime and boost.
References
[1]
World Malaria Report 2008. World Health Organization.
[2]
Bojang KA (2006) RTS,S/AS02A for malaria. Expert Rev Vaccines 5: 611–615.
[3]
Pombo D, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, et al. (2002) Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360: 610.
[4]
Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, et al. (2002) Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 1155–1164.
[5]
Tarun AS, Dumpit RF, Camargo N, Labaied M, Liu P, et al. (2007) Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. J Infect Dis 196: 608–616.
[6]
Wykes M, Good MF (2007) A case for whole-parasite malaria vaccines. Int J Parasitol 37: 705–712.
[7]
Mueller AK, Deckert M, Heiss K, Goetz K, Matuschewski K, et al. (2007) Genetically attenuated Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells. Am J Pathol 171: 107–115.
[8]
Druilhe P, Barnwell JW (2007) Pre-erythrocytic stage malaria vaccines: time for a change in path. Curr Opin Microbiol 10: 371–378.
[9]
Kumar KA, Sano G, Boscardin S, Nussenzweig RS, Nussenzweig MC, et al. (2006) The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 444: 937–940.
[10]
Perlaza BL, Valencia AZ, Zapata C, Castellanos A, Sauzet JP, et al. (2008) Protection against Plasmodium falciparum challenge induced in Aotus monkeys by liver-stage antigen-3-derived long synthetic peptides. Eur J Immunol 38: 2610–2615.
[11]
Perlaza BL, Zapata C, Valencia AZ, Hurtado S, Quintero G, et al. (2003) Immunogenicity and protective efficacy of Plasmodium falciparum liver-stage Ag-3 in Aotus lemurinus griseimembra monkeys. Eur J Immunol 33: 1321–1327.
[12]
Zapata JC, Perlaza BL, Hurtado S, Quintero GE, Jurado D, et al. (2002) Reproducible infection of intact Aotus lemurinus griseimembra monkeys by Plasmodium falciparum sporozoite inoculation. J Parasitol 88: 723–729.
[13]
Warren Mc Wilson, Contacos PeterG, G.Robert Coatney WEC (1971) The Primate Malarias. Bethesda: U.S. DEPARMENT OF HEALTH, EDUCATION, AND WELFARE. 366 p.
[14]
Vythilingam I, Tan CH, Asmad M, Chan ST, Lee KS, et al. (2006) Natural transmission of Plasmodium knowlesi to humans by Anopheles latens in Sarawak, Malaysia. Trans R Soc Trop Med Hyg 100: 1087–1088.
[15]
Cox-Singh J, Davis TM, Lee KS, Shamsul SS, Matusop A, et al. (2008) Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 46: 165–171.
[16]
Barnwell JW, Howard RJ, Coon HG, Miller LH (1983) Splenic requirement for antigenic variation and expression of the variant antigen on the erythrocyte membrane in cloned Plasmodium knowlesi malaria. Infect Immun 40: 985–994.
[17]
Rogers WO, Baird JK, Kumar A, Tine JA, Weiss W, et al. (2001) Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infect Immun 69: 5565–5572.
[18]
Rogers WO, Weiss WR, Kumar A, Aguiar JC, Tine JA, et al. (2002) Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen. Infect Immun 70: 4329–4335.
[19]
Weiss WR, Kumar A, Jiang G, Williams J, Bostick A, et al. (2007) Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens. PLoS ONE 2: e1063.
[20]
Rayner JO, Dryga SA, Kamrud KI (2002) Alphavirus vectors and vaccination. Rev Med Virol 12: 279–296.
[21]
Hubby B, Talarico T, Maughan M, Reap EA, Berglund P, et al. (2007) Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 25: 8180–8189.
[22]
Li S, Locke E, Bruder J, Clarke D, Doolan DL, et al. (2007) Viral vectors for malaria vaccine development. Vaccine 25: 2567–2574.
[23]
Earle WC, Perez M (1932) Enumeration of parasites in the blood of malarial patients. JLabClinMed 17: 1124–1130.
[24]
Charoenvit Y, Leef ML, Yuan LF, Sedegah M, Beaudoin RL (1987) Characterization of Plasmodium yoelii monoclonal antibodies directed against stage-specific sporozoite antigens. Infect Immun 55: 604–608.
[25]
Madin K, Sawasaki T, Ogasawara T, Endo Y (2000) A highly efficient and robust cell-free protein synthesis system prepared from wheat embryos: plants apparently contain a suicide system directed at ribosomes. Proc Natl Acad Sci U S A 97: 559–564.
[26]
Sawasaki T, Hasegawa Y, Tsuchimochi M, Kamura N, Ogasawara T, et al. (2002) A bilayer cell-free protein synthesis system for high-throughput screening of gene products. FEBS Lett 514: 102–105.
[27]
Sawasaki T, Gouda MD, Kawasaki T, Tsuboi T, Tozawa Y, et al. (2005) The wheat germ cell-free expression system: methods for high-throughput materialization of genetic information. Methods Mol Biol 310: 131–144.
[28]
Kumar A, Weiss W, Tine JA, Hoffman SL, Rogers WO (2001) ELISPOT assay for detection of peptide specific interferon-gamma secreting cells in rhesus macaques. J Immunol Methods 247: 49–60.
[29]
Jiang G, Charoenvit Y, Moreno A, Baraceros MF, Banania G, et al. (2007) Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization. Malar J 6: 135.
[30]
Voller A, Rossan RN (1969) Immunological studies on simian malaria. III. Immunity to challenge and antigenic variation in P. knowlesi. Trans R Soc Trop Med Hyg 63: 507–523.
[31]
Silvie O, Franetich JF, Charrin S, Mueller MS, Siau A, et al. (2004) A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem 279: 9490–9496.
[32]
Brice GT, Dobano C, Sedegah M, Stefaniak M, Graber NL, et al. (2007) Extended immunization intervals enhance the immunogenicity and protective efficacy of plasmid DNA vaccines. Microbes Infect 9: 1439–1446.
[33]
Stahl-Hennig C, Suh YS, Park KS, Sauermann U, Kim KS, et al. (2007) Immunogenicity of a DNA prime and recombinant adenovirus boost regime significantly varies between rhesus macaques of Chinese and Indian origins. J Med Primatol 36: 195–205.
[34]
Krzych U, Schwenk J (2005) The dissection of CD8 T cells during liver-stage infection. Curr Top Microbiol Immunol 297: 1–24.
[35]
Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig RS, et al. (1987) Gamma-interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330: 664–666.
[36]
Weiss WR, Sedegah M, Beaudoin RL, Miller LH, Good MF (1988) CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA 85: 573–576.
[37]
Jobe O, Lumsden J, Mueller AK, Williams J, Silva-Rivera H, et al. (2007) Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-gamma-producing CD8+ T cells. J Infect Dis 196: 599–607.
[38]
Stewart VA, McGrath SM, Dubois PM, Pau MG, Mettens P, et al. (2007) Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect Immun 75: 2283–2290.
[39]
Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA (2005) Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol 174: 7676–7683.
